PA5-21682

antibody from Invitrogen Antibodies

Targeting: IL17RD FLJ35755, IL-17RD, IL17RLM, SEF

Western blot (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-21682

Provider

Invitrogen Antibodies

Product name

IL17RD Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant protein fragment

Description

Recommended positive controls: 293T, A431, H1299, HeLaS3, NIH-3T3, mouse brain. Predicted reactivity: Mouse (89%), Rat (88%), Bovine (95%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.85 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

LncRNA NEAT1 promotes the tumorigenesis of colorectal cancer by sponging miR-193a-3p.

Yu HM, Wang C, Yuan Z, Chen GL, Ye T, Yang BW
Cell proliferation 2019 Jan;52(1):e12526

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 5 NEAT1 knockdown counteracted the tumour promoting effects of miR-193a inhibitor in CRC cells. A, B, MTT and cell colony formation assays showed that miR-193a inhibitor increased cell proliferative activity and colony formation capacity, but these tumour promoting effects induced by miR-193a were attenuated by NEAT1 knockdown in LOVO and HCT116 cell lines. C, TCGA data analysis of the expression level of IL17RD in pared CRC samples. D, TCGA data analysis of the correlation of IL17RD expression with miR-193a in CRC samples. E, qRT-PCR and Western blot analysis of the effects of lncRNA NEAT1 on the expression of IL17RD. F, G, qRT-PCR and Western blot analysis showed that miR-193a inhibitor increased the expression of IL17RD and this effect was reversed by NEAT1 knockdown in LOVO and HCT116 cell lines. * P < 0.05; ** P < 0.01